CD274 and neoplasm: Anti-PD-1/PD-L1 antibodies demonstrate their antitumor effects by inhibiting the interaction between PD-L1 and its receptor, PD-1, thereby activating cytotoxic T lymphocytes to attack and kill tumor cells [19,20,21].